Gilead Sciences, Inc. GILD announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the ...

Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy in the Phase 3 ARTISTRY 2 trial, with clean safety data that strengthens ...

Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...

A newly approved drug gives almost total protection against getting HIV. The FDA approved lenacapavir last week. Patients need just two injections of it a year to get that protection, but as NPR's ...

Please provide your email address to receive an email when new articles are posted on . Twice-yearly lenacapavir injections reduced HIV infections by 96% in a phase 3 trial. Gilead Sciences will begin ...

– European Commission Grants Marketing Authorization for Sunlenca, Helping to Address a Critical Unmet Clinical Need for People with Multi-Drug-Resistant HIV Who Have Very Limited Treatment Choices – ...